lncRNA NEAT1: Key player in neurodegenerative diseases

Kun Li; Ziqiang Wang

doi:10.1016/j.arr.2023.101878

lncRNA NEAT1: Key player in neurodegenerative diseases

Ageing Res Rev. 2023 Apr:86:101878. doi: 10.1016/j.arr.2023.101878. Epub 2023 Feb 3.

Authors

Kun Li¹, Ziqiang Wang²

Affiliations

¹ Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China.
² Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China; Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250062, China. Electronic address: wangziqiang@sdfmu.edu.cn.

PMID: 36738893
DOI: 10.1016/j.arr.2023.101878

Abstract

Neurodegenerative diseases are the most common causes of disability worldwide. Given their high prevalence, devastating symptoms, and lack of definitive diagnostic tests, there is an urgent need to identify potential biomarkers and new therapeutic targets. Long non-coding RNAs (lncRNAs) have recently emerged as powerful regulatory molecules in neurodegenerative diseases. Among them, lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) has been reported to be upregulated in Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). However, whether this is part of a protective or harmful mechanism is still unclear. This review summarizes our current knowledge of the role of NEAT1 in neurodegenerative diseases and its association with the characteristic aggregation of misfolded proteins: amyloid-β and tau in AD, α-synuclein in PD, mutant huntingtin in HD, and TAR DNA-binding protein-43 fused in sarcoma/translocated in liposarcoma in ALS. The aim of this review is to stimulate further research on more precise and effective treatments for neurodegenerative diseases.

Keywords: Gene regulation; NEAT1; Neurodegenerative disease; Therapeutic target; lncRNA.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / genetics
Amyotrophic Lateral Sclerosis*
Humans
Huntington Disease* / genetics
Neurodegenerative Diseases* / drug therapy
Neurodegenerative Diseases* / genetics
Parkinson Disease*
RNA, Long Noncoding* / genetics

Substances

RNA, Long Noncoding
NEAT1 long non-coding RNA, human